Hepatitis C Market Analysis, Size, Share & Growth Forecast 2026–2034

Mavyret 8-Week Pan-Genotypic Glecaprevir-Pibrentasvir 99 Percent SVR12 Across All 6 Genotypes in Treatment-Naive Non-Cirrhotic Patients Has Established the Shortest Approved HCV Cure Duration That Eliminates the Genotype Testing Requirement and the Ribavirin That Prior Regimens Required.The WHO 2030 HCV elimination targets require treating people who inject drugs as a priority population, but 3-5 annual reinfection rates per 100 person-years in active PWID mean that successful DAA treatment without concurrent needle exchange, opioid agonist therapy, and harm reduction support results in reinfection that sustains transmission chains. Australia, Iceland, and Scotland have demonstrated that integrating HCV treatment into opioid agonist therapy clinics and needle exchange programmes can achieve HCV cascade of care completion rates above 70% in PWID populations where conventional hepatology clinic models achieve under 30% treatment completion. The Pan-European HepCare programme and ANCHOR trial demonstrated that community pharmacist-based HCV testing and point-of-care RNA confirmation with same-day treatment initiation achieves treatment rates five times higher than specialist clinic referral in high-risk populations who are disengaged from traditional healthcare settings.

HCV NS5A RAS Testing Before NS5A Inhibitor Retreatment Guiding the Vosevi Triple Regimen Selection for the NS5A-Resistant Patient Has Established the Resistance-Guided Retreatment Algorithm That Overcomes the Prior DAA Failure Through the Additional Protease Inhibitor Voxilaprevir.AbbVie's glecaprevir-pibrentasvir Mavyret demonstrated 96.5% sustained virologic response at 12 weeks in NS5A-experienced and NS5A/NS3-naive patients in MAGELLAN-1, establishing salvage pan-genotypic therapy for the approximately 3-5% of patients who fail initial DAA treatment through non-adherence, reinfection, or resistance emergence. The second-line treatment of NS5A resistance-associated substitutions arising from elbasvir-grazoprevir and ledipasvir failure requires the high genetic barrier provided by pibrentasvir's fourth-generation NS5A inhibitor activity, and the 8-16-week pan-genotypic regimen achieves high cure rates without the resistance-associated substitution testing that first-generation salvage regimens required. The long-term virology monitoring of SVR24 durability beyond 12 weeks is confirming that HCV cure is permanent in the vast majority of patients without reinfection, establishing that achieving SVR12 is a sufficient endpoint for cure verification in clinical and regulatory settings.

HCV Micro-Elimination Targeting PWID, Incarcerated, Homeless, and High-Prevalence Migrant Populations Through Simplified Testing and Peer Navigator Treatment Access Is the Public Health Programme That WHO 2030 80 Percent Incidence Reduction Target Requires for the Hardest-to-Reach Populations.Long-term follow-up cohorts of HCV-cured patients in Scotland, the Netherlands, and the United States demonstrate 50-60% reductions in hepatocellular carcinoma incidence and 40% reductions in liver-related mortality at 5-10 years post-treatment compared with matched untreated or treatment-naive controls. The liver cancer prevention benefit of HCV cure generates healthcare cost offsets that strengthen cost-effectiveness arguments for investing in expanded DAA access programmes in lower-income countries where HCC treatment costs are quickly increasing as lifespans extend. The elimination of chronic HCV-driven cirrhosis and HCC progression creates a multi-decade downstream healthcare savings stream that health-economic models are increasingly incorporating into full lifetime cost-effectiveness analyses that support near-universal DAA access funding even at treatment costs of USD 1,000-2,000 per course in resource-limited settings.

For related market intelligence, see the Hepatitis B Market.